INFOSCUM.COM
Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week - MarketWatch
Published Date:
8/25/2022
Source:
news.google.com
Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week
MarketWatch
Pfizer COVID pill provides little or no benefit in adults 40 to 65
USA TODAY
Pfizer’s Paxlovid Excels at Treating Over 65s, Large Israeli Study Finds - Israel News
Haaretz
LI medical experts question Paxlovid study on symptoms in people under 65
Newsday
Paxlovid reduces risk of COVID-19 death by 81%, Clalit study shows
The Jerusalem Post
View Full Coverage on Google News
Read the Full Story Here
InfoScum.com